Sponsors (72)
The bill concentrates federal attention and multi‑year funding on uterine fibroids—improving research, information, and targeted outreach (especially for minority women)—but does so at a measurable taxpayer cost and with risks of administrative burden, diverted research priorities, uneven implementation, and some limits on choices and eligibility definitions.
Women with uterine fibroids (and patients with related chronic conditions) stand to gain from increased federal research and development that could produce better diagnostics, fertility‑preserving and minimally invasive treatments.
Researchers, clinical trial programs, and public health initiatives get predictable, multi‑year funding authorization (2026–2030), enabling sustained studies, trials, and outreach rather than one‑off projects.
Women—especially minority women—will have greater access to evidence‑based information and targeted outreach about non‑hysterectomy and fertility‑preserving options, improving awareness and earlier care‑seeking.
Taxpayers will face increased federal spending—including a specified $150 million discretionary cost over five years plus additional authorized but unspecified sums—raising budgetary costs.
Shifting federal research and program resources toward uterine fibroids risks diverting limited NIH/AHRQ funds from other diseases and research priorities if budgets are constrained.
State agencies, Medicaid programs, and healthcare providers may face new administrative and reporting burdens to supply data, adopt guideline materials, and participate in outreach efforts.
Based on analysis of 7 sections of legislative text.
Authorizes $30M/year (FY2026–2030) for coordinated uterine fibroid research, requires Medicaid/CHIP data collection/reporting, funds public education, and promotes evidence‑based care.
Expands federal research, data collection, education, and clinical outreach on uterine fibroids. It authorizes $30 million per year (FY2026–2030) for coordinated NIH research, directs HHS to build or expand a Medicaid/CHIP data set and report on expenditures, requires public education and evidence-based care promotion (including non‑hysterectomy options), and defines “minority individuals” by an existing Public Health Service Act definition. The law targets gaps in knowledge, racial disparities, and clinical practice by funding research, improving federal data on treatment use under Medicaid/CHIP, supporting public information campaigns, and encouraging specialty-society-guided evidence-based care and outreach to affected minority populations.
Official title: To provide for research and education with respect to uterine fibroids, and for other purposes.
Introduced July 15, 2025 by Yvette Diane Clarke · Last progress July 15, 2025